Fmoc-D-Dap(Dde)-OH

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-D-Dap(Dde)-OH
• 英文别名: (2R)-3-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
• 化学式: C₂₈H₃₀N₂O₆
• 分子量: 490.556
• InChiKey: IGNPBNCBFYUHTM-JOCHJYFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  36.0
• 可旋转键数：
  7.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  121.8
• 氢给体数：
  3.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  Fmoc-D-Dap(Dde)-OH 、 (S)-6-(3-aminopropoxy)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)quinazoline-4-carboxamide 在 2,4,6-三甲基吡啶 、 N-羟基-7-氮杂苯并三氮唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以30 %的产率得到(9H-fluoren-9-yl)methyl ((R)-1-((3-((4-((2-((S)-2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinazolin-6-yl)oxy)propyl)amino)-3-((1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)amino)-1-oxopropan-2-yl)carbamate
  参考文献：
  名称：

  [EN] RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP)
  [FR] RADIOTRACEURS ET AGENTS THÉRAPEUTIQUES SE LIANT À LA PROTÉINE D'ACTIVATION DES FIBROBLASTES (FAP)

  摘要：

  The present invention relates to a ligand-SIFA conjugate, comprising, within in a single molecule two separate moieties: (a) one or more ligands which are capable of binding to Fibroblast Activation Protein (FAP), and (b) a silicon-fiuoride acceptor (SI FA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom.

  公开号：

  WO2023283627A1

文献信息

• [EN] SILICON-CONTAINING LIGAND COMPOUNDS<br/>[FR] COMPOSÉS LIGANDS CONTENANT DU SILICIUM
  申请人：UNIV MUENCHEN TECH

  公开号：WO2022018264A1

  公开（公告）日：2022-01-27

  Provided is a ligand compound, comprising (a) a targeting group, (b) one or more chelating groups, optionally containing a chelated radioactive or non-radioactive cation, and (c) a group carrying an Si-OH functional moiety. The ligand compound is suitable for use in therapeutic or diagnostic methods, especially in radiotherapy or radiodiagnosis of cancer, such as prostate cancer.

  提供的是一种配体化合物，包括（a）一个靶向基团，（b）一个或多个螯合基团，可选地含有螯合的放射性或非放射性阳离子，以及（c）携带Si-OH功能基团的基团。该配体化合物适用于治疗或诊断方法，特别是在癌症的放射治疗或放射诊断中，如前列腺癌。
• WO2020157128A5
  申请人：——

  公开号：WO2020157128A5

  公开（公告）日：2022-12-23
• RADIOLABELED PSMA LIGAND COMPOUNDS AND PRECURSORS THEREOF
  申请人：[en]TECHNISCHE UNIVERSITÄT MÜNCHEN

  公开号：WO2024133174A1

  公开（公告）日：2024-06-27

  Provided is a PSMA-targeted ligand compound, which is a compound of formula (1) or a salt thereof, wherein RTis a PSMA binding group; L is a linking group; Rcis a trivalent coupling group; Rsis a silicon-containing moiety of the formula -C(O)-Rs3-SiRS1RS2OH, wherein RS1and RS2are independently selected from C3-C10 alkyl, and are preferably tert-butyl, and RS3is a group comprising a 6 membered aromatic ring, and is preferably benzenediyl; RAis an amino acid unit; and RCHis selected from (i) a branched-chain, acyclic chelating moiety having 4 amino groups, and (ii) a chelate moiety, wherein a radioisotope selected from99mTc,94mTc,186Re and188Re is chelated by the branched-chain, acyclic chelating moiety having 4 amino groups. The PSMA-targeted ligand compound in accordance with the invention is suitable for radiopharmaceutical applications, such as radioguided surgery.